Istiratumab

DB15363InvestigationalProtein Based Therapies

Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).

Mechanism: Pharmacologically active on Insulin-like growth factor 1 receptor and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Code names: MM-141

Resolves to

Compound

UNIIXLR461MD3MCAS1509928-04-4

Targets

P08069IGF1RP21860ERBB3

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Istiratumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account